SI2846780T1 - Raztopljena kapsulirana formulacija 1,1-dimetiletil((1S)-1-(((2S,4R)- 4-(7-kloro-4metoksiizokuinolin-1-iloksi)-2-(((1R,2S)-1- ((ciklopropilsulfonil)karbamoil)-2-etenilciklopropil)karbamoil) pirolidin-1-il)karbonil)-2,2- dimetilpropil)karbamata - Google Patents

Raztopljena kapsulirana formulacija 1,1-dimetiletil((1S)-1-(((2S,4R)- 4-(7-kloro-4metoksiizokuinolin-1-iloksi)-2-(((1R,2S)-1- ((ciklopropilsulfonil)karbamoil)-2-etenilciklopropil)karbamoil) pirolidin-1-il)karbonil)-2,2- dimetilpropil)karbamata

Info

Publication number
SI2846780T1
SI2846780T1 SI201331126T SI201331126T SI2846780T1 SI 2846780 T1 SI2846780 T1 SI 2846780T1 SI 201331126 T SI201331126 T SI 201331126T SI 201331126 T SI201331126 T SI 201331126T SI 2846780 T1 SI2846780 T1 SI 2846780T1
Authority
SI
Slovenia
Prior art keywords
carbamoyl
ethenylcyclopropyl
cyclopropylsulfonyl
dimethylpropyl
dimethylethyl
Prior art date
Application number
SI201331126T
Other languages
English (en)
Inventor
Robert Kevin Perrone
Original Assignee
Bristol-Myers Squibb Holdings Ireland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48428670&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2846780(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol-Myers Squibb Holdings Ireland filed Critical Bristol-Myers Squibb Holdings Ireland
Publication of SI2846780T1 publication Critical patent/SI2846780T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI201331126T 2012-05-07 2013-04-30 Raztopljena kapsulirana formulacija 1,1-dimetiletil((1S)-1-(((2S,4R)- 4-(7-kloro-4metoksiizokuinolin-1-iloksi)-2-(((1R,2S)-1- ((ciklopropilsulfonil)karbamoil)-2-etenilciklopropil)karbamoil) pirolidin-1-il)karbonil)-2,2- dimetilpropil)karbamata SI2846780T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261643454P 2012-05-07 2012-05-07
EP13722217.0A EP2846780B1 (en) 2012-05-07 2013-04-30 Solubilized capsule formulation of 1,1-dimethylethyl [(1s)-1-{[(2s,4r)-4-(7-chloro-4methoxyisoquinolin-1-yloxy)-2-({(1r,2s)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate
PCT/US2013/038770 WO2013169520A1 (en) 2012-05-07 2013-04-30 Solubilized capsule formulation of 1,1-dimethylethyl [(1s)-1-{[(2s,4r)-4-(7-chloro-4methoxyisoquinolin-1-yloxy)-2-({(1r,2s)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate

Publications (1)

Publication Number Publication Date
SI2846780T1 true SI2846780T1 (sl) 2018-09-28

Family

ID=48428670

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201331126T SI2846780T1 (sl) 2012-05-07 2013-04-30 Raztopljena kapsulirana formulacija 1,1-dimetiletil((1S)-1-(((2S,4R)- 4-(7-kloro-4metoksiizokuinolin-1-iloksi)-2-(((1R,2S)-1- ((ciklopropilsulfonil)karbamoil)-2-etenilciklopropil)karbamoil) pirolidin-1-il)karbonil)-2,2- dimetilpropil)karbamata

Country Status (33)

Country Link
US (1) US20130302414A1 (sl)
EP (1) EP2846780B1 (sl)
JP (1) JP6276756B2 (sl)
KR (1) KR20150004921A (sl)
CN (1) CN104363899A (sl)
AR (1) AR090954A1 (sl)
AU (1) AU2013260005B2 (sl)
BR (1) BR112014027676A2 (sl)
CA (1) CA2872765A1 (sl)
CL (1) CL2014003012A1 (sl)
CO (1) CO7141457A2 (sl)
CY (1) CY1120756T1 (sl)
DK (1) DK2846780T3 (sl)
EA (1) EA028749B1 (sl)
ES (1) ES2688817T3 (sl)
HK (1) HK1204552A1 (sl)
HR (1) HRP20181583T1 (sl)
IL (1) IL235466B (sl)
LT (1) LT2846780T (sl)
MX (1) MX358545B (sl)
MY (1) MY171378A (sl)
NZ (1) NZ630248A (sl)
PE (1) PE20142439A1 (sl)
PH (1) PH12014502405A1 (sl)
PL (1) PL2846780T3 (sl)
PT (1) PT2846780T (sl)
RS (1) RS57881B1 (sl)
SG (1) SG11201406964QA (sl)
SI (1) SI2846780T1 (sl)
TW (1) TWI577392B (sl)
UY (1) UY34785A (sl)
WO (1) WO2013169520A1 (sl)
ZA (1) ZA201408967B (sl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013169577A1 (en) * 2012-05-07 2013-11-14 Bristol-Myers Squibb Company Oral solid dosage formulation of 1,1-dimethylethyl [(1s)-1-{[(2s,4r)-4-(7-chloro-4methoxyisoquinolin-1-yloxy)-2-({(1r,2s)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate
EA025560B1 (ru) 2012-10-19 2017-01-30 Бристол-Майерс Сквибб Компани Ингибиторы вируса гепатита с
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014070964A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2014071007A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP2914614B1 (en) 2012-11-05 2017-08-16 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2014137869A1 (en) 2013-03-07 2014-09-12 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2019130341A1 (en) * 2017-12-26 2019-07-04 Hetero Labs Limited Capsule compositions comprising lopinavir and ritonavir

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9710071B (en) * 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.
ATE381922T1 (de) * 2000-10-31 2008-01-15 Boehringer Ingelheim Pharma Perorale, selbst-emulgierende darreichungsformen von pyranon-proteaseinhibitoren
US6828301B2 (en) * 2002-02-07 2004-12-07 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for hepatitis C viral protease inhibitors
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
TWI480272B (zh) * 2008-10-09 2015-04-11 Anadys Pharmaceuticals Inc 藉由５，６－二氫－１ｈ－吡啶－２－酮與一或多種其他抗病毒化合物的組合物抑制ｃ型肝炎病毒的方法
US8252821B2 (en) * 2009-04-14 2012-08-28 Bristol-Myers Squibb Company Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound

Also Published As

Publication number Publication date
MX358545B (es) 2018-08-24
DK2846780T3 (en) 2018-09-17
CO7141457A2 (es) 2014-12-12
HK1204552A1 (en) 2015-11-27
PH12014502405A1 (en) 2015-01-12
AU2013260005A1 (en) 2015-01-15
ZA201408967B (en) 2016-10-26
EP2846780A1 (en) 2015-03-18
PT2846780T (pt) 2018-10-26
IL235466B (en) 2019-03-31
TWI577392B (zh) 2017-04-11
EA201492039A1 (ru) 2015-02-27
US20130302414A1 (en) 2013-11-14
EA028749B1 (ru) 2017-12-29
EP2846780B1 (en) 2018-07-18
PE20142439A1 (es) 2015-01-28
CA2872765A1 (en) 2013-11-14
ES2688817T3 (es) 2018-11-07
CN104363899A (zh) 2015-02-18
LT2846780T (lt) 2018-11-12
WO2013169520A1 (en) 2013-11-14
JP2015516418A (ja) 2015-06-11
NZ630248A (en) 2016-11-25
MX2014013220A (es) 2015-05-11
UY34785A (es) 2013-11-29
TW201350145A (zh) 2013-12-16
CY1120756T1 (el) 2019-12-11
CL2014003012A1 (es) 2015-07-10
MY171378A (en) 2019-10-10
HRP20181583T1 (hr) 2018-11-30
JP6276756B2 (ja) 2018-02-07
KR20150004921A (ko) 2015-01-13
PL2846780T3 (pl) 2018-11-30
RS57881B1 (sr) 2019-01-31
BR112014027676A2 (pt) 2017-06-27
SG11201406964QA (en) 2014-11-27
AR090954A1 (es) 2014-12-17
AU2013260005B2 (en) 2017-07-13

Similar Documents

Publication Publication Date Title
SI2846780T1 (sl) Raztopljena kapsulirana formulacija 1,1-dimetiletil((1S)-1-(((2S,4R)- 4-(7-kloro-4metoksiizokuinolin-1-iloksi)-2-(((1R,2S)-1- ((ciklopropilsulfonil)karbamoil)-2-etenilciklopropil)karbamoil) pirolidin-1-il)karbonil)-2,2- dimetilpropil)karbamata
EP2917180A4 (en) GPR40 RECEPTOR AGONIST, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE SUBSTANCE
AU2013225533A8 (en) Amido spirocyclic amide and sulfonamide derivatives
WO2013152059A8 (en) Multicolored ph-activatable fluorescence nanoplatform
IL252900A0 (en) Formulations of 2-(tert-butylamino)-4-((1r,3r,4r)-3hydroxy-4-methycyclohexylamino)-pyrimidine-5-carboxamide
WO2011150201A3 (en) Azolyl amide compounds and methods of use thereof
IL247077B (en) A pharmaceutical preparation containing a diamino heterocyclic carboxamide compound as an active ingredient
HK1204937A1 (en) Pharmaceutical composition comprising (1r,4r)-6-fluoro-n,n-dimethyl- 4-phenyl-4,9-dihydro-3h-spiro[cyclohexane-1,1-pyrano [3,4,b]indol]-4-amine and an anticonvulsant (1r4r)-6--nn--4--49--3h-[- 11-[34b]]-4-
MY169048A (en) Polymorph of n- (2-methoxybenzoyl) -4- [(methylaminocarbonyl) amino] benzenesulfonamide
EP2871187A4 (en) NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AS ACTIVE INGREDIENT
WO2015095659A3 (en) Indirubin solid dispersion composition
HK1204943A1 (en) Pharmaceutical composition comprising (1r,4r)-6-fluoro-n,n-dimethyl- 4-phenyl-4,9-dihydro-3h-spiro[cyclohexane-1,1-pyrano [3,4,b]indol]-4-amine and a gabapentinoid (1r4r)-6--nn--4--49--3h-[-1 1-[34b]]-4-
WO2014159501A3 (en) Processes for preparing tetrahydroisoquinolines
HK1204938A1 (en) Pharmaceutical composition comprising (1r,4r)-6-fluoro-n,n-dimethyl- 4-phenyl-4,9-dihydro-3h-spiro[cyclohexane-1,1-pyrano [3,4,b]indol]-4-amine and a nsar (1r4r)-6--nn--4--49--3h-[- 11-[34b]]-4- nsar
WO2013033602A3 (en) Fatty acid amides, compositions and methods of use
TH1401006625A (th) สูตรผสมแคปซูลที่ละลายได้ของ 1,1-ไดเมธิลเอธิล[(1s)-1{[2s,4r)-4-(7-คลอโร-4เมธอกซีไอโซควิโนลิน-1-อิลออกซี)-2-({1r,2s)-1-[(ไซโคลโพรพิลซัลโฟนิล) คาร์บาโมอิล]-2-เอธีนิลไซโคลโพรพิล}คาร์บาโมอิล)ไพร์โรลิดิน-1-อิล]คาร์บอนิล}-2,2-ไดเมธิลโพรพิล]คาร์บาเมต
HK1204944A1 (en) Pharmaceutical composition comprising (1r,4r)-6-fluoro-n,n-dimethyl- 4-phenyl-4,9-dihydro-3h-spiro[cyclohexane-1,1-pyrano [3,4,b]indol]-4-amine and antidepressants (1r4r)-6--nn--4--49--3h-[- 11-[34b]]-4-
HK1204940A1 (en) Pharmaceutical composition comprising (1r,4r)-6-fluoro-n,n-dimethyl- 4-phenyl-4,9-dihydro-3h-spiro[cyclohexane-1,1- pyrano[3,4,b]indol]-4-amine and paracetamol or propacetamol (1r4r)-6--nn--4--49--3h-[- 11-[34b]]-4-
PL2678006T3 (pl) Pakowanie stałych preparatów farmaceutycznych zawierających substancję aktywną triazotan glicerolu
HK1204939A1 (en) Pharmaceutical composition comprising (1r,4r)-6-fluoro-n,n-dimethyl- 4-phenyl-4,9-dihydro-3h-spiro[cyclohexane-1,1-pyrano [3,4,b]indol]-4-amine and an oxicam (1r4r)-6--nn--4--49--3h-[- 11-[34b]]-4-
HK1204941A1 (en) Pharmaceutical composition comprising (1r,4r)-6-fluoro-n,n-dimethyl- 4-phenyl-4,9-dihydro-3h-spiro [cyclohexane-1,1-pyrano- [3,4,b]indol]-4-amine and a salicylic acid component (1r4r)-6--nn--4--49--3h-[- 11-[34b]]-4-
BR112014028557A2 (pt) composição farmacêutica compreendendo ( 1r , 4r )-6-fluoro-n ,n-dimetil-4-fenil-4 ,9-di-hidro-3h-espiro[ciclohexano-1 ,1-pirano-[3,4,b]indol]-4- amina e um anticonvulsivo
WO2015037017A3 (en) Pharmaceutical compositions of roflumilast and process for preparation thereof